コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 L1CAM expressing TLS are most common in mismatch-repair
2 L1CAM is a transmembrane protein expressed on neurons th
3 L1CAM knock-out mice show hypoplasia of the corticospina
4 L1CAM regulates expression of NBS1, a critical component
5 L1CAM(+) and CD133(+) cells cosegregated in gliomas, and
6 L1CAM-positive extracellular vesicles (L1EV) are an emer
7 L1CAM-positive extracellular vesicles (L1EV) were immuno
8 ically downstream of the MNR-1/Menorin-SAX-7/L1CAM adhesion complex and upstream of the DMA-1 recepto
11 two transmembrane ligands on the skin, SAX-7/L1CAM and MNR-1, and the neuronal transmembrane receptor
12 elopment requires the adhesion protein SAX-7/L1CAM and the cytoplasmic protein GRDN-1/CCDC88C to anch
15 OA binds to CASY-1/calsyntenin in AVG; SAX-7/L1CAM in sensory neuron PHC binds to RIG-6/contactin in
16 with the neural cell adhesion molecule SAX-7/L1CAM in the skin and through the neuronal leucine-rich
18 LECT-2 localization is dependent on SAX-7/L1CAM, but not on MNR-1/Menorin or DMA-1/LRR-TM, suggest
19 ions between MAGI-1, AFD-1/afadin, and SAX-7/L1CAM, which are part of a functional interactome that i
21 rn was instructed by adhesion molecule SAX-7/L1CAM, which formed regularly spaced stripes on the hypo
24 rtem material from a 2-week-old male with an L1CAM mutation revealed normal corticospinal decussation
27 ons among proteins of the APP, contactin and L1CAM families, with general implications for mechanisms
32 state in neuroblastoma as well as GSK3B and L1CAM that are involved in neuronal cell adhesion and mi
34 etabolic reprogramming, as well as LOXL2 and L1CAM, which encode proteins that are required for lung
37 son with the presumed NDEV markers NCAM1 and L1CAM by using super-resolution microscopy and biochemic
39 glioma cells both in vitro and in vivo, and L1CAM may represent a cancer stem cell-specific therapeu
41 r prevention mouse model, (161)Tb-based anti-L1CAM radioimmunotherapy as a new therapeutic modality a
42 e clinics by establishing (161)Tb-based anti-L1CAM radioimmunotherapy as a novel therapeutic modality
44 SCs more efficiently than (177)Lu-based anti-L1CAM radioimmunotherapy, emphasizing its promising ther
46 erived exosomes (NDEs) were enriched by anti-L1CAM antibody immunoabsorption from plasmas of subjects
48 We demonstrate that treatment with the anti-L1CAM antibody Ab417 decreases L1CAM overexpression and
49 mmunocapture of neuronal exosomes using anti-L1CAM antibodies, prior to the array-based assaying of a
50 ently extracted from patient sera using anti-L1CAM conjugated zwitterionic polymer-modified magnetic
52 ion molecule, L1CAM, in glioma stem cells as L1CAM regulates brain development and is expressed in gl
53 ism for L1CAM regulation of cell survival as L1CAM knockdown decreased expression of the basic helix-
54 e MMP16 substrate MMP14 (MT1-MMP) as well as L1CAM cell adhesion molecule, identified here as a novel
55 bjects we found that the association between L1CAM interactions and memory maintenance revealed large
57 n inhomogeneous surface distribution of both L1CAM and TrkA in various neural cells including neurons
58 int activation and radioresistance caused by L1CAM knockdown, demonstrating that L1CAM signals throug
62 yonic stem (ES) cells carrying a conditional L1CAM loss-of-function mutation and produced precisely m
63 e Sema3A receptor, Npn1, and its coreceptor, L1CAM, while the ERM C-terminal domain binds and caps F-
66 with the anti-L1CAM antibody Ab417 decreases L1CAM overexpression and nuclear translocation and persi
68 usly, we identified a role of the C. elegans L1CAM homolog, SAX-7, in maintaining neuronal and axonal
71 Thus, our findings identify PyN-expressed L1CAM as a critical CAM required for innervation of neoc
72 an increased number of exosomes enriched for L1CAM, a marker predominantly expressed in the brain, in
75 tennary N-glycans with select preference for L1CAM and other N-glycoproteins with multiple N-glycans
78 expression analyses demonstrate that AR-FUT4-L1CAM-AJs signaling correlates with pathological staging
80 Consequentially, REST-targeted neural genes (L1CAM, beta3-tubulin, synaptophysin, and others) are der
81 on chromosome X in two known disease genes, L1CAM and PAK3, and in two novel candidate CP genes, CD9
82 analysis of CUT&Tag with RNA-seq highlighted L1CAM (L1 cell adhesion molecule), a known endothelial-t
86 uirement for the cell surface targets IGF2R, L1CAM and SLC31A1 in tumor cell growth in vitro, and sug
88 relationship between expression of IRS-1 in L1CAM(+) exosomes and systemic IR as assessed by homeost
90 the insulin receptor substrate-1 (IRS-1) in L1CAM(+) exosomes in subjects with MDD as compared with
94 cell membrane lipid microdomains, increased L1CAM cleavage by plasmin, and increased shedding of cle
95 condary to neural cell adhesion molecule L1 (L1CAM) gene mutations includes the distinct finding of b
96 e gene for neural cell adhesion molecule L1 (L1CAM) result in a debilitating X-linked congenital diso
98 e main or sole clinical feature, 2 X-linked (L1CAM and AP1S2) and 2 autosomal recessive (CCDC88C and
99 demonstrate that the Drosophila melanogaster L1CAM homologue Neuroglian mediates adhesion between fun
100 Strikingly, we found the L1 family member L1CAM to be the only molecule required for ChC/PyN AIS i
102 (2019) identify the cell adhesion molecule L1CAM as integral to the mechanism by which chandelier c
105 y inactivating the axon pathfinding molecule L1CAM, which metastatic cells express for spreading alon
106 tations involving L1 cell adhesion molecule (L1CAM) and integrin signaling pathways; and (iv) APOBEC-
109 ousal, and of the L1 cell adhesion molecule (L1CAM) interactions gene set with the repetition-based m
112 sion, among which L1 cell adhesion molecule (L1CAM) was significantly higher upon a reduction of C1QB
115 FUT4 fucosylates L1 cell adhesion molecule (L1CAM), which is required for FUT4-increased metastatic
116 beads to isolate L1 cell adhesion molecule (L1CAM)-positive extracellular vesicles with characterist
118 mutations in the L1 cell adhesion molecule (L1CAM, hereafter abbreviated L1) were identified in L1 s
119 e role of a neuronal cell adhesion molecule, L1CAM, in glioma stem cells as L1CAM regulates brain dev
120 se expression of the cell adhesion molecule, L1CAM, in the brains of CWH43 mutant mice and in human H
121 -pass transmembrane cell adhesion molecules (L1CAMs) is conserved from Caenorhabditis elegans and Dro
123 neral EV marker CD9 and markers for neurons (L1CAM, CD171), astrocytes (EAAT1), and oligodendrocytes
124 ng vascular DNA damage by inhibiting nuclear L1CAM translocation might effectively prevent anticancer
126 f PyN AISs by ChCs requires AIS anchoring of L1CAM by the cytoskeletal ankyrin-G/betaIV-spectrin comp
127 osylation of L1CAM, decreased association of L1CAM with cell membrane lipid microdomains, increased L
129 ed directly the diffusion characteristics of L1CAM on the upper surface of ND-7 neuroblastoma hybrid
130 vascular fibrosis and the colocalization of L1CAM and DNA damage foci, while Ab417 attenuates these
132 nt ES cell clones, we found that deletion of L1CAM dramatically impaired axonal elongation and, to a
134 letion leads to decreased N-glycosylation of L1CAM, decreased association of L1CAM with cell membrane
138 tive ADF/cofilin and reduced by knockdown of L1CAM.Together, these data suggest that ERM proteins org
140 cells cosegregated in gliomas, and levels of L1CAM were higher in CD133(+) glioma cells than normal n
142 ls that regulate tyrosine phosphorylation of L1CAM members and modulate their binding to ankyrin.
143 of this study was to confirm the presence of L1CAM(+)/CD133(+) ovarian CSCs in patient samples and pr
144 s suggest that the clinical presentations of L1CAM mutations in human patients could be accounted for
147 necessary and sufficient for the skipping of L1CAM transmembrane domain in ECs, leading to the releas
148 h glioma xenograft model, shRNA targeting of L1CAM expression in vivo suppressed tumor growth and inc
151 ults implicate ankyrin-based localization of L1CAMs in subcellular organization of GABAergic synapses
155 hese genes demonstrated that loss of GAS6 or L1CAM sensitized cells to cisplatin, but that loss of HM
156 ut not on those binding exclusively Itgb1 or L1CAM, DS GCs were significantly enlarged (2.0-fold), fo
159 tumor analysis confirmed that sorted ovarian L1CAM(+)/CD133(+) CSCs regenerated the tumor heterogenei
161 nd the levels of the neural adhesion protein L1CAM and the transferrin receptor (TFR1) are significan
162 by anti-human CD171 neural adhesion protein (L1CAM) antibody and extracted proteins quantified with E
163 by NGF, but also by the L1 adhesion protein, L1CAM, whose soluble construct binds the receptor with s
165 istochemistry and co-immunofluorescence show L1CAM expression in mature TLS, independent of L1CAM exp
167 on of neural marker proteins, synaptophysin, L1CAM, NeuN, and GFAP was not significantly altered by E
168 stem cell tumor growth in vivo, we targeted L1CAM in glioma cells before injection into immunocompro
174 aused by L1CAM knockdown, demonstrating that L1CAM signals through NBS1 to regulate DNA damage checkp
178 Taken together, these results indicate that L1CAMs constitute a family of ubiquitous adhesion molecu
179 ofascin, which is highly conserved among the L1CAM family of cell adhesion molecules, and describes s
181 tis elegans animals genetically null for the L1CAM homologue LAD-1, exhibit variably penetrant pleiot
184 yrin binding to neurofascin, a member of the L1CAM family of nervous system cell adhesion molecules.
185 xpression of wild-type L1CAM, but not of the L1CAM point mutants R1166X and S1224L, rescued the decre
188 licing factor NOVA2, which binds directly to L1CAM pre-mRNA, is necessary and sufficient for the skip
190 with persistent DNA damage show upregulated L1CAM and EndMT, indicating clinical applicability of Ab
192 tor that inhibits EC-EC interaction, whereas L1CAM increases the adherence of BrCa cells to ECs.
196 A with high REST PC12 cells transfected with L1CAM documented the transactivation of the receptor by